- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AV-101, Placebo
- Drug
- Lead sponsor
- Aerovate Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 7,451
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- LY900003
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 20
- States / cities
- Hot Springs, Arkansas • Springdale, Arkansas • Los Angeles, California + 17 more
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ublituximab
- Biological
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 19
- States / cities
- Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
- Conditions
- AML, MDS
- Interventions
- SOC + TSC-101, Control, SOC + TSC-100
- Drug · Other
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- obinutuzumab (RO5072759), rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease, Valvular Disease, Chronic Stable Angina, Chronic Stable Heart Failure
- Interventions
- Hospital-based CR + Movn Application, Choice of Hospital or home-based CR + Movn Application, Hospital-based CR + Movn Application + Nudge, Choice of Hospital or home-based CR + Movn Application + Nudge
- Other
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
- Interventions
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 13
- States / cities
- La Mesa, California • Orange, California • Denver, Colorado + 9 more
- Conditions
- Head and Neck Cancer
- Interventions
- Induction chemotherapy, cisplatin, fluorouracil, low-LET cobalt-60 gamma ray therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Melanoma (Skin)
- Interventions
- irofulven
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Denver, Colorado • Park Ridge, Illinois + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
- Drug · Procedure
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Self-management support education, Connection to Health Interactive Behavior Change Technology, Connection to Health plus Coaching (CTH+C)
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Constipation, Chronic Idiopathic Constipation, CIC
- Interventions
- BLI400 Laxative, BLI400 Placebo
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
- Conditions
- Non Squamous Non Small Cell Lung Cancer
- Interventions
- OGX-427, Placebo
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 16
- States / cities
- Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more
- Conditions
- Hyponatremia
- Interventions
- conivaptan
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 7
- States / cities
- Tuscon, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 280
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 99
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
- Conditions
- Solid Tumor, Metastatic Colorectal Cancer
- Interventions
- dasatinib, bevacizumab, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- Herbert Hurwitz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Durham, North Carolina
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Placebo, Vortioxetine, Duloxetine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 781 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 66
- States / cities
- Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 25
- States / cities
- Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, ifosfamide, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
- Conditions
- Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Interventions
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Drug
- Lead sponsor
- CARGO Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 60
- States / cities
- Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
- Conditions
- Ulcerative Colitis
- Interventions
- Placebo, PF-00547659 SC Injection
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 99
- States / cities
- Scottsdale, Arizona • La Jolla, California • Orange, California + 49 more